Shenzhou Jiamei Pharmaceutical

Shenzhou Jiamei Pharmaceutical is a clinical-stage biopharmaceutical company headquartered in Beijing, China, dedicated to the discovery and development of innovative small molecule drugs. The company focuses primarily on metabolic and chronic liver diseases, with a specialized emphasis on the Farnesoid X receptor (FXR) pathway. Its lead candidate, SJM-1602, is a potent and selective FXR agonist currently undergoing Phase 2 clinical evaluation for the treatment of non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC). By leveraging its internal research capabilities, Shenzhou Jiamei aims to address significant unmet medical needs in hepatology and gastroenterology.